Related Experiment Video
Updated: Oct 25, 2025
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.3K
[B-cell acute lymphoblastic leukemia with glycophorin A expression]
Yosuke Matsumoto1, Mio Sugitani1, Rina Nishikawa1
1Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital.
Summary
This study presents a rare case of B-cell acute lymphoblastic leukemia expressing an erythroid marker. Further research is needed to understand this mixed phenotype acute leukemia (MPAL) entity.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Mixed phenotype acute leukemia (MPAL) classification remains challenging.
- The World Health Organization (WHO) criteria do not explicitly define erythroid lineage in MPAL.
- Biphenotypic leukemia involving lymphoid and myeloid/erythroid lineages is exceptionally rare.
Observation:
- A 49-year-old woman presented with B-cell acute lymphoblastic leukemia.
- The leukemia cells expressed glycophorin A, a known erythroid marker.
- This represents one of the few reported cases of erythroid/B-cell biphenotypic acute leukemia.
Findings:
- The case highlights the heterogeneity of acute lymphoblastic leukemia.
- Expression of erythroid markers in B-cell ALL challenges current diagnostic paradigms.
- This finding suggests a potential shared developmental pathway or aberrant differentiation.
Implications:
- Further investigation is crucial to establish erythroid/lymphoid MPAL as a distinct disease entity.
- Understanding the pathophysiology of this rare MPAL subtype may reveal new therapeutic targets.
- Analysis of additional cases is necessary to clarify diagnostic criteria and treatment strategies.
